Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has announced the resignation of Ms. Stephanie Vipond as Joint Company Secretary due to maternity leave, with Mr. Cameron Jones continuing as the sole Company Secretary. The Australian antiviral drug development company is also eyeing a Priority Review Voucher upon potential FDA approval of their lead dengue fever treatment, ISLA-101, which could accelerate future drug approvals or be monetarily valuable if sold.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
